These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35236775)

  • 1. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.
    Wang X; Jiang L; Thao K; Sussman CR; LaBranche T; Palmer M; Harris PC; McKnight GS; Hoeflich KP; Schalm S; Torres VE
    J Am Soc Nephrol; 2022 Jun; 33(6):1087-1104. PubMed ID: 35236775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
    Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
    Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
    J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
    Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
    Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.
    Chaudhary A; He Z; Atwood DJ; Miyazaki M; Oto OA; Davidoff A; Edelstein CL
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1004-F1015. PubMed ID: 38634129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1
    Arroyo J; Escobar-Zarate D; Wells HH; Constans MM; Thao K; Smith JM; Sieben CJ; Martell MR; Kline TL; Irazabal MV; Torres VE; Hopp K; Harris PC
    Kidney Int; 2021 Jun; 99(6):1392-1407. PubMed ID: 33705824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
    Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
    Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cGAS Activation Accelerates the Progression of Autosomal Dominant Polycystic Kidney Disease.
    Yoo M; Haydak JC; Azeloglu EU; Lee K; Gusella GL
    J Am Soc Nephrol; 2024 Apr; 35(4):466-482. PubMed ID: 38247039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of P-TEFb by cAMP-PKA signaling in autosomal dominant polycystic kidney disease.
    Sun Y; Liu Z; Cao X; Lu Y; Mi Z; He C; Liu J; Zheng Z; Li MJ; Li T; Xu D; Wu M; Cao Y; Li Y; Yang B; Mei C; Zhang L; Chen Y
    Sci Adv; 2019 Jun; 5(6):eaaw3593. PubMed ID: 31183407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
    Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
    Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures.
    Natoli TA; Gareski TC; Dackowski WR; Smith L; Bukanov NO; Russo RJ; Husson H; Matthews D; Piepenhagen P; Ibraghimov-Beskrovnaya O
    Am J Physiol Renal Physiol; 2008 Jan; 294(1):F73-83. PubMed ID: 17928412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small hairpin inhibitory RNA delivery in the metanephric organ culture identifies long noncoding RNA
    Eckberg K; Weisser I; Buttram D; Somia N; Igarashi P; Aboudehen KS
    Am J Physiol Renal Physiol; 2022 Sep; 323(3):F335-F348. PubMed ID: 35862648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
    Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
    Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD.
    Rogers KA; Moreno SE; Smith LA; Husson H; Bukanov NO; Ledbetter SR; Budman Y; Lu Y; Wang B; Ibraghimov-Beskrovnaya O; Natoli TA
    Physiol Rep; 2016 Jun; 4(12):. PubMed ID: 27356569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
    Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
    Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
    Hopp K; Hommerding CJ; Wang X; Ye H; Harris PC; Torres VE
    J Am Soc Nephrol; 2015 Jan; 26(1):39-47. PubMed ID: 24994926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nedd9 restrains renal cystogenesis in Pkd1-/- mice.
    Nikonova AS; Plotnikova OV; Serzhanova V; Efimov A; Bogush I; Cai KQ; Hensley HH; Egleston BL; Klein-Szanto A; Seeger-Nukpezah T; Golemis EA
    Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12859-64. PubMed ID: 25139996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.
    Hopp K; Ward CJ; Hommerding CJ; Nasr SH; Tuan HF; Gainullin VG; Rossetti S; Torres VE; Harris PC
    J Clin Invest; 2012 Nov; 122(11):4257-73. PubMed ID: 23064367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.